Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1- infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA

AIDS Research and Human Retroviruses

Volumn 15, Issue 11, 1999, Pages 963-972

  Kaufmann, Gilbert R ^a   Zaunders, John J ^a   Cunningham, Philip ^a   Cooper, David A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DIDANOSINE; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; VIRUS REPLICATION;

ADP-RIBOSYL CYCLASE; ADULT; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD38; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; L-SELECTIN; MALE; MEMBRANE GLYCOPROTEINS; NAD+ NUCLEOSIDASE; PHENOTYPE; RITONAVIR; RNA, VIRAL; SAQUINAVIR;

EID: 0033587665     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310476     Document Type: Article

References (33)

1. Egger M, Hirschel B, Francioli P, et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland. Br Med J 1997;315:1194-1199.
2. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
3. Kelleher AD, Carr A, Zaunders J, and Cooper DA: Alterations in the immune response of human immunodeficiency virus (HlV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-329.
4. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 197;277:112-116.
5. Cavert W, Notermans DW, Staskus K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-964.
6. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
7. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
8. Wong JK, Marjan H, Gunthardt HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
9. Kaufmann GR, Duncombe C, Cunningham P, et al.: Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HlV-1 infected individuals. AIDS 1998;12:1625-1630.
10. Bouscarat F, Levacher M, Landman R, et al.: Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998;12:1267-1273.
11. Carr A, Emery S, Kelleher A, Law M, and Cooper DA: CD8+ responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr 1996;13:320-326.
12. Gray CM, Schapiro JM, Winters MA, and Merigan TC: Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998;14:561-569.
13. Pakker NG, Notermans DW, De Boer RJ, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med 1998;4:208-214.
14. Vingerhoets J, Dohlsten M, Penne G, et al.: Superantigen activation of CD4+ and CD8+ T cells from HIV infected subjects: Role of costimulatory molecules and antigen-presenting cells. Clin Exp Immunol 1998;111:12-19.
15. Schoenberger SP, Tose RE, van der Voort EI, Offringa R, and Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (London) 1998;393:413-114.
16. Angel JB, Kumar A, Parato K, et al.: Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir and saquinavir. J Infect Dis 1998; 177:898-904.
17. Prince HE and Jensen ER: Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr 1991;4:1227-1232.
18. Margolick JB, Farzadegan H, Hoover DR, and Saan AJ: Relationship between infectious cell-associated human immunodeficiency virus type 1 load, T lymphocyte subsets, and stage of infection in homosexual men. J Infect Dis 1995;173:468-471.
19. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, and Bach BA: The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: Staging and prognostic value. Clin Exp Immunol 1992;90:376-382.
20. Giorgi JV, Ho HN, Hirji K, Chou CC, Hultin LE, Orourke S, et al.: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion-development of HLA-DR+ CD38-CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis 1994;170(4):775-781.
21. Giorgi JV, Liu ZY, Hultin LE, Cumberland WG, Hennessey K, and Detels R: Elevated levels of CD38+CD8+ T-cells in HIV infection add to the prognostic value of low CD4+ T-cell levels - results of 6 years of follow-up. J Acquir Immune Defic Syndr 1993;6(8):904-912.
22. Liu ZY, Cumberland WG, Hultin LE, Prince HE, Detels R, and Giorgi JV: Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr 1997;16(2):83-92.
23. Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, et al.: CD8+, CD38+ lymphocyte percent - a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr 1997;14(2):158-162.
24. Bouscarat F, Levacherclergeot M, Dazza MC, Strauss KW, Girard PM, Ruggeri C, et al.: Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Hum Retrovir 1996;12(1):17-24.
25. Roederer M, Dubs JG, Anderson MT, et al.: CD8 naive T cell counts decrease progressively in HIV-1 infected adults. J Clin Invest 1995;95:2061-2066.
26. Butz EA and Bevan MJ: Massive expansion of antigen-specific CD8+ cells during acute virus infection. Immunity 1998; 8:167-175.
27. Tough DF, Borrow P, and Sprent J: Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996;272:1947-1950.
28. Fauci AS, Pantaleo G, Stanley S, and Weissman D: Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996; 124:654-663.
29. Murali-Krishna K, Altman JD, Suresh M, et al.: Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection. Immunity 1998;8:177-187.
30. Hawke S, Stevenson PG, Freeman S, and Bangham C: Long-term persistence of activated cytotoxic T lymphocytes after viral infection of the central nervous system. J Exp Med 1998;187: 1575-1582.
31. Lynne JE, Schmid I, Matud JL, et al.: Major expansion of select CD8+ subsets in acute Epstein-Barr virus infection. J Infect Dis 1998;177:1083-1087.
32. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, and Poggi C: Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/ml. J Infect Dis 1998;177:235-238.
33. Wong JK, Gunthard HF, Havlir DV, et al.: Reduction of HIV in blood and lymph nodes after potent antiretroviral therapy. In: 4th Conference on Retroviruses and Opportunistic Infections: Program and Abstracts (Washington DC). Infectious Disease Society of America, Alexandria; Virginia, 1997. [Abstract LB10]